DAYBUE. Slide Please X, beginning Thank turn you, with Steve. to
by key and the growth value for drivers Let potential discussing they start X me long-term the continued represent. of DAYBUE
DAYBUE, date, we approval. lot XX% -- diagnosed to now received X have successful market we've year patients pursue significantly to been room patients patient still product a a with Rett we of remaining approximately of of the awareness large with where X population growth treated, caregiver out in has penetrating post we segment. have X higher this centers share so now have First, about the in Launch to physician excellence, that having and of treatment grow
we're prescriptions excellence, today of patient of COEs We're depth where driving our an exists. focusing the on expect outside high-volume in moving the potential majority also share of community source of noncenter shift and and In to of prescribing already from addition, practices increasing forward. seeing a come institutions
us a of foundation launch, a providing is evidence X following real-world benefits. year real Second, levers. the world Number now we have into
observed are share X enhance the with best will doctors is describing DAYBUE. We're quotes successful meaningful and accelerate of We real-world from course, GI starting seeing as may in We right when and that the take as disease titrate approaches, In a serving longer well community.
Number is have see across time and GI as weeks, benefit to patients X majority wide of of caregivers dose. severities are their guidance an key in range may ages with sharing of and families expectations seeing consideration. by a therapeutic you families of strategies. management about establishment their from a ensure It's over treatment a take practices patients. wide know management. the further benefits moment, therefore to Number of that to We've the range we a treatment observe the GI to a patients physicians titrating I examples learnings benefits. are several time get of regarding of to to benefits period they're the it some a it opportunity important key successful is management and
of patient. sufficient for happen benefits on frame observed that not importance treatment families, appropriate the that early work GI time together emphasizes to realize have expectations We out To to HCPs DAYBUE appropriate or line these the time messaging many an dose working on strategy may a patient's benefits get our the discontinuations produces determine appropriate support a to caregivers management have in treatment GI the setting regimen. each been further that and a management and of
out is like time XX study We deeper patients. persistency open-label a driver points the now have percentage was of data on in these persistency the dive into observed LILAC each that This launch.
I'd seen rollover placebo the the extension of to X-month we've for third take above to drivers. consistent tracking demonstrates continues curve Our persistency mark from therapy. what
launch, growing opportunity started more patient in let's Rett from where have that of DAYBUE market on which a we these penetration year growth and XX% approximately patients. leaves market One patients ample us X,XXX come diagnosed in for with X,XXX First, COEs, we've discuss share, patients potential. setting. than into Many
of well from enhanced and X/X on tolerability prescriptions of split shifting more experience prescriptions excellence, excellence X/X with is Our with of outside community even of of to institutions of Rett the from we're an X/X DAYBUE centers to mix centers excellence noncenter both patients as is these from of practices.
Since high-volume management from level clinical as strategies. prescribers lower, treating to expect delivering messaging benefits coming
to We're a DAYBUE, stories success the encourage ages created adoption. the to and Our and on post educate second prescribers success to on stories starting which severities. prescribing these evidence staying now utilizing successes what motivate has is DAYBUE. across have key of many caregivers and expect both those range Broad when to treatment will early and broader HCPs driver DAYBUE launch led and real-world to initiate families disease
of Looking GI wide pretty a range seen management we've approaches. at strategies,
dialed feel GI they much Some to labeling physicians and COEs, achieve this have a practices, the strategies utilizing success. and very particularly of management in, few product
of in guidelines. these there strategies community is telling to important is variable, the further educate us broader these opportunity However, on implementation an
we've our time. trial to comparing launch that best tracking, be to over persistency to post-launch very experience. management a GI seen very where we've in been support when communicating driver, clinical our by longitudinal persistency consistent next base to implementation the very believe patients enduring debuts pattern in rate will continue clinical encouraged more since the a building consistent sizable we benefits, further we rate While of of addition consistent practices This persistency of leads of
cohorts latest XX% with is our persistency X now rollover real-world in share With now persistency X at rate months, the LILAC patients data. me seen for Let out patient to months. placebo XX% compared
last been to could This continue see therapy percentage on build we of sizable trial track years. and we we therapy call, patients a population our As to X.X half If enduring therapy patients points initiated than DAYBUE experience, our clinical XX be the initiate approximately approximately DAYBUE. have on who enduring more believe on we in therapy. the opportunity Phase underscores remain of that XX% above population on II on comparison today approximately for described
Let on we patients me the therapy. of touch on number have
DAYBUE figures As we therapy we of active on compared XXX XX the February patients on XXX. the shared May of with have X, week ending
digested.
I'd as continue yet patients view not yet tried several we the we now X,XXX recap been on patients most increase largely part year thousand quarter believe described observed last opportunity our During first discontinuations grow market. first who is We've to like our of net we to a therapy substantially over in on discontinuation in additions in saw the peaked diagnosed, due in and we the not decline and have of opportunity who Steve DAYBUE. numerical the now now have of patients X each quarter, patient and in active increase the earlier. numerical the seen an we to DAYBUE Rett in With commence weeks, to have U.S. diagnosed has an second
Our benefiting from enduring a experience date can to we population indicates sizable DAYBUE. persistency build
a build to States. have large a of prescribing to foundation and strong our outside access.
Please including a discussion XX DAYBUE Slide payer on, broad for We the United plans population on turn
beyond are markets. toward rapidly available U.S., in additional we Looking making the DAYBUE advancing
review filing our paving which scheduled agreed XXXX. the upon quarter submission have plan, Health PMDA first granted has in for EMA, detailed plan. for Canada, Japan, with around priority our the Pediatric anticipated completed the an approval filing investigation PIP, or of in clinical Canada, end pediatric drug the the to clinical announced previously trials recently we And potentially Our In now year. Committee an proposed with in meeting by leading this for of quarter and accepted been of that way market we a formal the later DAYBUE discuss this to was that new the
Let's turn Slide now to XX.
some noting and a broadening consistent feedback decreased the use stereotypies. Here, with caregivers caregivers observations in of ringing higher many you described vocabulary levels months, improved with and of the as of from purposeful and been above, more conversations, improvement see hearing for quotes reinforcing in hands such we've engagement engagement, each of hand speech
improvements quality hear with patients do to benefit We in we conversations. DAYBUE view increased well also testimonials to the being what increased patients as all tell life greatest feedback able underscore they to now or for these regularly as better families. exactly why us Caregivers cognitive care of as about with loved meaningful the in ones of ability follow alertness enhancements with and ACADIA speak These at their and their those promise do we the treatment needs. support
start Slide financial XX I'll discussion NUPLAZID reiterating a Let's optimize primary do turn X for NUPLAZID to of we ways. our flow, in and with that our franchise. to cash objective that by is
new to than has to allowed launched the market our broad on the patient First, recently studies. we're to and attention bottle starts most shipments in have to growth These drive market grow grow market. share PDP. for real-world year, efforts continuing eighth bringing year effective lever our we us campaign evidence been The educational the last faster
flow by have These to and stand-alone, generate million annual continue to managing we carefully burdened XXXX. throughout enabled combined do that on NUPLAZID we'll $XXX second cash efforts cash in fully expenses, us way basis The franchise a is flow. optimize over
sales. turn to NUPLAZID to product delivered Slide first our performance. $XXX.X let's net review in In Now million quarter XXXX, of quarterly XX the
with largely disease flat while As with increased quarter compared quarter essentially both this and the in first year. versus evidenced antipsychotics on of TRxs their prior last fourth flat slide, respectively, by the X%, presented carbidopa-levodopa remains prescription the X% Parkinson's in NUPLAZID market the and data both quarter other
care and channels. PD market outperformed both the the NUPLAZID Importantly, office-based long-term in growth in
franchise.
I'll Strategic to recent by XX. continuing Manhard, to an Senior starting now trends pipeline forward programs it our Kimberly on grow turn execution to of this to and Slide are We President Vice encouraged Planning over Global and look these update on provide
